Mergers and Acquisitions — The 5 Biggest Deals of Q2

These companies led the mergers and acquisitions charge in Q2

      View All  
Mergers and Acquisitions — The 5 Biggest Deals of Q2

Top Mergers and Acquisitions: Novartis (NVS) and GlaxoSmithKline (GSK)

Novartis185 Mergers and Acquisitions    The 5 Biggest Deals of Q2The aborted Pfizer bid for AZN means that the pharma industry’s largest consummated deal came only to $20 billion. That’s the total value of assets that Novartis (NVS) and GlaxoSmithKline (GSK) agreed to swap in what amounted to major restructurings for both firms.

Novartis bought GlaxoSmithKline’s cancer drug business, GSK took Novartis’s vaccine business, and the companies agreed to combine their respective over-the-counter and consumer drug businesses. Whew.

All the big pharmaceuticals players are desperately trying to “focus” their businesses (read: cuts costs until revenue comes back), and — on paper, at least — this deal makes sense.


Article printed from InvestorPlace Media, http://investorplace.com/2014/06/mergers-and-acquisitions-buyouts/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.